​Hormone replacement therapy, or HRT, was the first menopause treatment available to women, approved by the FDA in 1941. It ...

Many doctors agree with the Food and Drug Administration’s recent decision to remove the black box warnings on at least some ...

Menopause represents a profound systemic shift involving cardiovascular, skeletal, and neurological health, requiring ...

The FDA approved Addyi (flibanserin), a libido-enhancing drug, in postmenopausal women under the age of 65. Experts explain ...

On December 15, 2025, the U.S. Food and Drug Administration approved the medication Addyi for the treatment of hypoactive ...

A tenuous connection between hormone therapy and increased dementia risk was noted, but more research is warranted. In A ...

The FDA expanded its approval of Addyi to treat low libido in postmenopausal women up to age 65. The approval will open up ...

The findings show no evidence to suggest that hormone replacement therapy (HRT) either increases or decreases dementia risk ...

For these women, menopause wasn’t to be experienced quietly. With the help of their doctors and the right treatment option, ...

The analysis, published in The Lancet Healthy Longevity, concluded there was “n o significant association” between HRT and ...

With the black box warning a thing of the past, interest in these once-controversial medications is growing, say experts.

The once-a-day treatment, which acts on brain chemicals that affect mood and appetite, had initially been OK’d for ...